- Home
- NWFL vs NMRA Comparison
NWFL vs NMRA Comparison
Compare NWFL & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NWFL | NMRA |
|---|---|---|
| Founded | 1870 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.1M | 311.3M |
| IPO Year | 1996 | 2023 |
Fundamental Metrics
Financial Performance| Metric | NWFL | NMRA |
|---|---|---|
| Price | $31.77 | $1.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $33.00 | $7.50 |
| AVG Volume (30 Days) | 52.2K | ★ 3.6M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | ★ 15150.00 | 5.23 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $7,999,000.00 | N/A |
| Revenue This Year | $34.35 | N/A |
| Revenue Next Year | $5.55 | N/A |
| P/E Ratio | $86.46 | ★ N/A |
| Revenue Growth | ★ 8.11 | N/A |
| 52 Week Low | $23.70 | $0.83 |
| 52 Week High | $32.86 | $3.65 |
Technical Indicators
Market Signals| Indicator | NWFL | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout NWFL Norwood Financial Corp.
Norwood Financial Corp is a U.S.-based bank holding company. It offers various personal and business credit services, trust and investment products, and real estate settlement services to consumers, businesses, nonprofit organizations, and municipalities in each of the communities that the bank serves. The bank also manages automated teller machines at its branch location. It serves the Pennsylvanian counties of Wayne, Pike, Monroe, and Lackawanna, as well as Susquehanna County.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.